22 scheduled presentations, including 10 oral presentations, examining blood cancers and other key hematology research
NEW BRUNSWICK, N.J., Dec. 2, 2020 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its hematology clinical research program will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually from December 5-8. A total of 22 abstracts have been accepted, predominantly data in several types of blood cancers, including leukemia, lymphoma and myeloma.
"At Rutgers Cancer Institute of New Jersey and RWJBarnabas Health our team of internationally recognized physicians and translational researchers all share the same singular focus and mission, which is to help individuals eradicate cancer," said Andrew M. Evens, DO, MSc, FACP, Associate Director for Clinical Services and Director, Lymphoma Program, Rutgers Cancer Institute and Medical Director, Oncology Service Line, RWJBarnabas Health. "In line with this mission, and despite the challenges presented by the COVID-19 pandemic, we remain wholeheartedly committed to our oncology clinical research program and look forward to sharing our robust lineup of data in blood cancers and other key areas of hematology research at ASH."
Of the 22 abstracts, 10 were accepted for oral presentation. Highlights of Rutgers Cancer Institute of New Jersey speakers include:
The full list of presentations at this year's ASH Annual Meeting and Exposition follows:
Oral Presentations |
||
Abstract and |
Title |
Presentation Date/Time |
| (Session 653) |
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) |
Saturday, December 5, 2020 |
Abstract 271 |
Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium |
Saturday, December 5, 2020 |
Abstract 400 |
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy |
Sunday, December 6, 2020 |
Abstract 476 |
Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era |
Sunday, December 6, 2020 |
Abstract 478 |
CNS Prophylaxis During Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions |
Sunday, December 6, 2020 at 2:30 p.m. PST |
Abstract 527 |
Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor |
Monday, December 7, 2020 |
Abstract 599 |
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study |
Monday, December 7, 2020 |
Abstract 586 |
Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001 |
Monday, December 7, 2020 |
Abstract 705 |
The Burkitt Lymphoma International Prognostic Index (BL-IPI) |
Monday, December 7, 2020 |
Abstract 706 |
Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis |
Monday, December 7, 2020 |
Poster Presentations |
||
Abstract and |
Title |
Presentation Date/Time |
Abstract 1102 |
Genomic Ancestry in B Cell Lymphoid Malignancies |
Saturday, December 5, 2020 |
Abstract 1190 |
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen |
Saturday, December 5, 2020 |
Abstract 1407 |
A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma |
Saturday, December 5, 2020 |
Abstract 2066 |
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium |
Sunday, December 6, 2020 |
Abstract 2046 |
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study |
Sunday, December 6, 2020 |
Abstract 2801 |
Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance |
Sunday, December 6, 2020 |
Abstract 2503 |
Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL) |
Sunday, December 6, 2020 |
Abstract 2478 |
Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings |
Sunday, December 6, 2020 |
Abstract 2101 |
Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL) |
Sunday, December 6, 2020 |
Abstract 3297 |
Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population |
Monday, December 7, 2020 |
Abstract 2978 |
Radiation-Based Approaches as an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis |
Monday, December 7, 2020 |
Abstract 3051 |
EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort |
Monday, December 7, 2020 |
About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
908-812-6114
[email protected]
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)
SOURCE Rutgers Cancer Institute of New Jersey; RWJBarnabas Health
Share this article